ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to “Hold” by Zacks Investment Research

ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “

Other equities analysts have also issued research reports about the company. BidaskClub lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Guggenheim assumed coverage on ANI Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $76.00 price target on the stock. Finally, ValuEngine lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $86.40.



ANIP stock traded up $2.84 during midday trading on Thursday, reaching $72.48. The company’s stock had a trading volume of 272,942 shares, compared to its average volume of 121,380. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The stock has a fifty day simple moving average of $72.13 and a two-hundred day simple moving average of $71.51. ANI Pharmaceuticals has a 1 year low of $36.92 and a 1 year high of $86.96. The firm has a market capitalization of $835.38 million, a price-to-earnings ratio of 15.72 and a beta of 2.22.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.26. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The business had revenue of $54.36 million for the quarter, compared to analyst estimates of $55.20 million. During the same quarter last year, the firm posted $1.13 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. As a group, analysts forecast that ANI Pharmaceuticals will post 5.29 EPS for the current fiscal year.

In other news, major shareholder Meridian Venture Partners Ii L sold 19,860 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $71.70, for a total transaction of $1,423,962.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 98,451 shares of company stock worth $7,006,801. Insiders own 24.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Hancock Whitney Corp grew its stake in ANI Pharmaceuticals by 1.4% in the second quarter. Hancock Whitney Corp now owns 11,446 shares of the specialty pharmaceutical company’s stock valued at $941,000 after purchasing an additional 155 shares during the last quarter. Nomura Holdings Inc. grew its stake in ANI Pharmaceuticals by 34.1% in the second quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock valued at $31,071,000 after purchasing an additional 95,462 shares during the last quarter. Royal Bank of Canada grew its stake in ANI Pharmaceuticals by 186.8% in the second quarter. Royal Bank of Canada now owns 2,765 shares of the specialty pharmaceutical company’s stock valued at $227,000 after purchasing an additional 1,801 shares during the last quarter. First Manhattan Co. grew its stake in ANI Pharmaceuticals by 22.8% in the second quarter. First Manhattan Co. now owns 294,852 shares of the specialty pharmaceutical company’s stock valued at $24,236,000 after purchasing an additional 54,686 shares during the last quarter. Finally, United Services Automobile Association purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $224,000. Institutional investors own 70.76% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.